Full Breakdown
Mandatory CCTV Surveillance for Prescription Drug Sales in Indian Medical Stores
By Drooid · · How we work
Proposed Regulation Overview
A draft notification issued by the Ministry of Health and Family Welfare on September 8, 2026 proposes that the supply of any drug prescribed by a registered medical practitioner—except wholesale transactions—must occur under a Closed-Circuit Television (CCTV) system installed and maintained at the licensed premises. The recordings are to be retained for a minimum of three months. The measure is presented as a way to make prescription-drug dispensing verifiable and to curb unauthorised over-the-counter sales, particularly of medicines that should not be given without medical supervision.
Background and Context
India’s Drugs Rules, 1945 already require that medicines listed under Schedules H, H1 and X be sold only against a valid prescription, with additional record-keeping for certain categories. Recent regulatory scrutiny has focused on cough syrups and other formulations that were previously exempt from prescription requirements. The current proposal expands oversight by adding a surveillance and record-retention component, rather than creating a new prescription mandate limited to those schedules.
The amendment was first deliberated by the Drugs Consultative Committee (DCC) and subsequently reviewed by the Drugs Technical Advisory Board (DTAB), which recommended approval before the draft was placed in the Gazette.
Timeline
- September 8 – Gazette notification invites objections and suggestions on the draft amendment (30-day comment period).
- September 8, 2026 – Draft notification released, outlining the CCTV requirement and three-month retention rule.
- September 17, 2026 – Media reports highlight the proposal and its intended impact on Schedule H, H1 and X drug oversight.
Data and Statistics
- Retention period: CCTV footage must be kept for at least three months.
- Comment window: Stakeholders may submit feedback for 30 days from the Gazette’s release.
- Scope: Applies to all prescription-based drug sales at licensed retail premises; wholesale dealers are excluded.
Official Statements & Responses
The ministry explained that the CCTV mandate is an “additional regulatory safeguard” aimed at strengthening monitoring of the sale and distribution of Schedule H, H1 and X drugs. A senior health official clarified that the draft’s wording is broader, covering any drug supplied on a registered practitioner’s prescription rather than naming specific schedules. Government sources indicated that the proposal seeks to improve accountability at the point of dispensing and to provide regulators with a visual record for investigating suspected violations.
Conflicting Reports & Gaps
Some outlets emphasize that the draft explicitly targets Schedule H, H1 and X medicines, while others note that the language does not name these schedules and instead applies to any prescription-based drug. The lack of a final rule means the exact scope and implementation details remain uncertain, and no quantitative estimate of the expected impact on illegal sales has been provided.
Verbatim Quotes
- “The comments can be sent to the Under Secretary (Drugs), Ministry of Health and Family Welfare or emailed to drugsdiv-mohfw@gov.in,” — the ministry
What’s Next
The Ministry of Health and Family Welfare has invited objections and suggestions to be sent to the Under Secretary (Drugs) at the Ministry’s address or via email to drugsdiv-mohfw@gov.in. Submissions received within the 30-day window will be considered before the amendment is potentially finalized and published in the Official Gazette, at which point a commencement date will be specified.